Zevra testing beta blocker celiprolol for vEDS in Phase 3 US study
Zevra Therapeutics has been enrolling and dosing new patients in a Phase 3 clinical trial testing celiprolol, a beta blocker being developed for people with vascular Ehlers-Danlos syndrome (vEDS) caused by mutations in the COL3A1 gene. The trial, dubbed DiSCOVER (NCT05432466), is assessing how well celiprolol works…